Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**lactobacillus plantarum DSM 9843 + iron** is a combination of the probiotic strain *Lactobacillus plantarum* DSM 9843 (commonly known as LP299V) and an iron supplement, used together primarily to improve iron absorption and gastrointestinal tolerability in individuals with iron deficiency or at risk of iron deficiency anemia. LP299V has demonstrated the ability to increase non-heme iron absorption, likely through mechanisms such as the reduction of ferric to bioavailable ferrous iron, enhancing mucin production at the intestinal surface, and modulating the immune response to reduce hepcidin-mediated inhibition of iron transport. This combination aims to address the poor gastrointestinal tolerance often associated with oral iron therapy, improving both iron bioavailability and patient compliance[1][3][5]. The combination has been supported in multiple studies for increasing iron uptake and ferritin levels, especially in populations with increased iron needs, such as athletes and pregnant women, with better GI tolerability compared to iron supplementation alone[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus plantarum DSM 9843 + iron.